8 citations
,
December 2023 in “International Journal of Molecular Sciences” Lower TNF-α levels in PRP may predict better treatment outcomes for bladder conditions.
December 2022 in “Acta Ophthalmologica” Dutasteride potentially improves cell survival and reduces retinal damage in retinitis pigmentosa.
Finasteride significantly reduces prostate cancer risk.
January 2014 in “cIRcle (University of British Columbia)” Photoacoustic imaging can detect prostate brachytherapy seeds better with enhanced contrast methods, but depth limits remain.
December 2004 in “SUNScholar (Stellenbosch University)” Certain genetic markers can indicate a person's risk of developing prostate cancer.
3 citations
,
September 2023 in “Prostate Cancer and Prostatic Diseases”
Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.
January 2026 in “Andrology” PRP injections are safe but don't significantly improve Peyronie's Disease.
386 citations
,
April 2006 in “PubMed” BPH is common in older men and often occurs with other age-related health issues.
January 2005 in “Metas de Enfermería” Serenoa repens may help with prostate issues, but more research is needed to confirm its effectiveness.
1 citations
,
September 2025 in “Archivio Italiano di Urologia e Andrologia” Serenoa repens extract, alone or with other supplements, improves urinary symptoms and lowers PSA levels.
1 citations
,
August 2020 in “REMUS - Revista Estudiantil de Medicina de la Universidad de Sonora” Erectile dysfunction is linked to marital issues in patients with benign prostatic hyperplasia.
Women with androgenetic alopecia (hair loss) have normal prostate specific antigen levels but higher testosterone levels.
5 citations
,
June 2015 in “Chinese journal of natural medicines/Zhongguo tianran yaowu/Chinese Journal of Natural Medicines” Tripterygium wilfordii multiglycoside effectively reduced prostate enlargement in rats without harmful effects.
June 2006 in “American Journal of Epidemiology” Long-term diabetes is linked to lower prostate cancer risk.
1 citations
,
April 2023 in “World Journal of Urology” Finasteride reduces some inflammation in BPH but not all.
5 citations
,
July 2021 in “medRxiv (Cold Spring Harbor Laboratory)” Proxalutamide improved blood markers related to inflammation, immune response, and clotting in COVID-19 patients, potentially reducing hospitalizations.
April 2017 in “The Journal of urology/The journal of urology” SHH protein helps nerve regeneration in hypertensive rats.
April 2013 in “The FASEB Journal” Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.
3 citations
,
March 2005 in “The Journal of urology/The journal of urology” Dutasteride may help shrink prostate cancer tumors.
45 citations
,
August 2010 in “Hormone Molecular Biology and Clinical Investigation” Type 3 5α-reductase is more common and finasteride and dutasteride strongly inhibit it.
14 citations
,
January 2003 in “Actas Urológicas Españolas” Finasteride effectively reduces symptoms of enlarged prostate with minimal side effects.
17 citations
,
January 2013 in “Talanta” A new method was developed to accurately measure enzyme activity related to prostate health.
January 2018 in “Repositorio de Tesis - UNMSM” Physalis peruviana extract is more effective in treating benign prostatic hyperplasia in rats than finasteride and terazosine.
4 citations
,
November 2005 in “The Journal of Urology” Large prostates link to more hair loss.
2 citations
,
January 2009 in “The Journal of Internal Korean Medicine” Scutellaria baicalensis may help treat benign prostatic hyperplasia.
March 2009 in “The Journal of Urology” Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.
January 2009 in “Journal of Jilin Medical College” SDG helps reduce BPH effects in rats.
1 citations
,
July 2022 in “Cancer Epidemiology, Biomarkers & Prevention” 5-Alpha reductase inhibitors are safe long-term but may be outdated for preventing less significant prostate cancer.
March 2014 in “Annals of Internal Medicine” Combining α1-blockers with 5α-reductase inhibitors improves urinary symptoms in men.